1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
Insomnia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Insomnia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • July 2021
  • 125 pages
  • ID: 6106034
  • Format: PDF
  • Mordor Intelligence LLP

Summary

Table of Contents

Search Inside

The global insomnia treatment market was valued at USD 2,898 million in 2020, and it is expected to reach USD 4,065 million by 2026, registering a CAGR of 5.93% during the forecast period.

Globally, the COVID-19 pandemic has produced unprecedented changes in lives. For many people, it has generated significant stress, anxiety, and worries about health, social isolation, employment, finances, as well as the challenge of combining work and family obligations. Such a major stressful life event is also likely to have impaired sleep and shows an impact on market growth. For instance, according to the American Academy of Sleep Medicine (AASM) Sleep Prioritization Survey 2020, the US adults reported that the COVID-19 pandemic has impacted sleep. About one-third (33%) of adults have experienced an impact to sleep quality, 30% have seen a change in their ability to fall asleep and 29% noted an impact on the nightly amount of sleep. In addition, females were more likely to report that bedtimes (31%) are impacted by the COVID-19 pandemic than males (25%).

Also, =the increasing prevalence of insomnia, rising stress levels, and increasing awareness about various treatment options for this condition are some of the factors expected to propel the market.

According to the American Psychological Association (APA), the Stress in America survey, in 2020, on a scale of 1 to 10, adults rated their stress levels as 5.0, compared to that of 2019, which was 4.9. Moreover, stress levels among Gen Z adults have been increasing slightly over the past two years, i.e., from 5.6 in 2018 and 5.8 in 2019, and 6.1 recorded in 2020. Insomnia hardly occurs in isolation and is usually comorbid with other conditions. Rather than just treating the primary disorder, whereby symptoms of insomnia may go unnoticed or unaddressed, presently there is a push to recognize the existence of chronic insomnia as a disorder, which itself merits treatment. Insomnia patients have increased risk for psychiatric disorders, particularly depression, anxiety, increased healthcare utilization and costs, decreased quality of life, drug, or alcohol abuse, decreased occupational performance, and increased accidents.

Development of new technologies and introduction of medical devices are anticipated to boost market growth. The major market players are playing a significant role in the market. For instance, in June 2020, Eisai Co. Ltd received approval from the US Food and Drug Administration (FDA) and the firm launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the United States.

The other factors such as side effects due to certain OTC and prescription medication, arthritis, high usage of media devices before sleep, are driving the number of people suffering from insomnia, thus boosting the market growth prospects. Moreover, the growth of psychological conditions and constantly increasing noise levels in the urban areas will also propel the insomnia treatment market, during the forecast period. However, the misconceptions about the seriousness of insomnia and patient non adherence to the treatment are some of the factors that are expected to restraint market growth over the forecast period.

Key Market Trends
Orexin Antagonist Segment is Expected to Grow in the Forecast Period

Reduced efficacy and harmful side effects constrain the use of such treatment options for several patients. Suvorexant (MK-4305, Merck), an ORA (orexin receptor antagonist), is the first in a new class of drugs for treating insomnia. The tablets endorse the natural transition from sleeplessness to sleep by hindering the wakefulness-promoting orexin neurons of the arousal system. Suvorexant advances sleep onset, as well as sleep maintenance. This distinctive alternative has advantageous permissibility and a restricted side-effect profile.

Suvorexant is a potent dual orexin receptor antagonist that blocks both receptors, i.e., OX1R and OX2R. It stimulates sleep through the binding inhibition of orexin-A and B, neuropeptides that promote wakefulness.

Approximately 70,000 orexin neurons are there in the human brain, located in the perifornical lateral hypothalamus, which sends signals throughout the brain and spinal cord. Suvorexant’s mechanism of action varies from that of the benzodiazepines and non-benzodiazepines since it has no effect on Gamma-aminobutyric acid (GABA). As an alternative to promoting sleep, it inactivates wakefulness.

In December 2019, the US Food and Drug Administration (FDA) approved the new drug application for Easai’s in-house discovered and developed orexin receptor antagonist DAYVIGOTM (lemborexant). DAYVIGO was approved for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults.

Owing to the advancements associated with this class of drugs, the segment is expected to observe a steady growth over the forecast period.

North America is Expected to Dominate the Insomnia Treatment Market

North America leads the insomnia treatment market. The growing need for sleep disorder treatment in the US and Canada coupled with the growing prevalence of sleep disorders is driving the market over the forecast period. According to the American Academy of Sleep Medicine 2020, stress can result in adjustment insomnia, which may affect up to 20% of people in the United States each year. Poor sleeping habits in children lead to behavioral insomnia of childhood, affecting 30% of children. Prescription drugs, substance abuse, medical disorders, and mental health conditions cause insomnia, with about 3% of the population having this type of sleep issue. Specific causes include depression, drug withdrawal, obesity, and anemia.

Additionally, the presence of supportive organizations specific to insomnia in the country is also a major driving factor for the market. The Canadian Sleep Society is one such national organization committed to improving sleep for all Canadians through support for research, promotion of high-quality clinical care, education of professionals and the public, and advocacy for sleep and sleep disorders medicine.

Moreover, the presence of key market players and the Research and Development of new drugs and product launches are expected to boost the growth of the market studied.

For instance, in July 2019, Zydus Cadila launched Ramelteon tablets, used to treat insomnia, in the US market. Similarly, in June 2020, Eisai Co. Ltd launched in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. All these factors are projected to increase the growth of the insomnia treatment market in the North America.

Competitive Landscape
The insomnia treatment market is fragmented in nature owing to the presence of multiple generic manufacturers. A few players operating in the market offer branded drugs options, however, price sensitivity is an issue in several emerging regions. Additionally, major manufacturers are focusing on the development of new molecules to gain a competitive edge and tap the high unmet needs in the market. The major players in the market are Merck & Co., Ebb Therapeutics, Paratek Pharmaceuticals, Inc., Pfizer Inc., Sanofi S.A., Electromedical Products International Inc., Takeda Pharmaceutical Company Ltd., Cerêve Inc., and Innovative Neurological Devices

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Insomnia (Central Nervous System) - Drugs in Development, 2021

  • $ 2000
  • September 2021
  • 169 pages

Insomnia (Central Nervous System) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Drugs In Development, 2021, provides an overview of the ...

  • World
  • Australia
  • Sleep Aid
  • Drug Development
  • Industry analysis
  • Depression Prevalence
  • Diagnostic Imaging Density

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on